Skip to main content

Advertisement

SpringerLink
Log in

Multimodality molecular imaging — from target description to clinical studies

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

This highlight lecture was presented at the closing session of the Annual Congress of the European Association of Nuclear Medicine (EANM) in Munich on 15 October 2008. The Congress was a great success: there were more than 4,000 participants, and 1,597 abstracts were submitted. Of these, 1,387 were accepted for oral or poster presentation, with a rejection rate of 14%. In this article a choice was made from 100 of the 500 lectures which received the highest scores by the scientific review panel. This article outlines the major findings and trends at the EANM 2008, and is only a brief summary of the large number of outstanding abstracts presented. Among the great number of oral and poster presentations covering nearly all fields of nuclear medicine some headlines have to be defined highlighting the development of nuclear medicine in the 21st century. This review focuses on the increasing impact of molecular and multimodality imaging in the field of nuclear medicine. In addition, the question may be asked as to whether the whole spectrum of nuclear medicine is nothing other than molecular imaging and therapy. Furthermore, molecular imaging will and has to go ahead to multimodality imaging. In view of this background the review was structured according to the single steps of molecular imaging, i.e. from target description to clinical studies. The following topics are addressed: targets, radiochemistry and radiopharmacy, devices and computer science, animals and preclinical evaluations, and patients and clinical evaluations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

Similar content being viewed by others

References

  1. Bischof Delaloye A, Carrió I, Cuocolo A, Knapp W, Gourtsoyiannis N, McCall I, et al. White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging. Eur J Nucl Med Mol Imaging 2007;34:1147–51. doi:10.1007/s00259-007-0494-2.

    Article  PubMed  Google Scholar 

  2. Gourtsoyiannis N, McCall I, Reiser M, Silberman B, Bischof Delaloye A, Carrió I, et al. White paper of the European Society of Radiology (ESR) and the European Association of Nuclear Medicine (EANM) on multimodality imaging. Eur Radiol 2007;17:1926–30. doi:10.1007/s00330-007-0698-7.

    Article  PubMed  Google Scholar 

  3. Stegger L, Schäfers M, Weckesser M, Schober O. EANM-ESR white paper on multimodality imaging. Eur J Nucl Med Mol Imaging 2008;35:677–80. doi:10.1007/s00259-008-0724-2.

    Article  PubMed  Google Scholar 

  4. Carrió I. EANM-ESR white paper on multimodality imaging. Eur J Nucl Med Mol Imaging 2008;35:673. doi:10.1007/s00259-008-0725-1.

    Article  PubMed  Google Scholar 

  5. Cuocolo A, Adam A. The “White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging": a message from the EANM and ESR Presidents. Eur J Nucl Med Mol Imaging 2007;34:1145–6. doi:10.1007/s00259-007-0495-1.

    Article  PubMed  Google Scholar 

  6. Adam A, Cuocolo A. The "White paper of the European Society of Radiology (ESR) and the European Association of Nuclear Medicine (EANM) on multimodality imaging": a message from the ESR and EANM Presidents. Eur Radiol 2007;17:1924–5. doi:10.1007/s00330-007-0699-6.

    Article  PubMed  Google Scholar 

  7. Biersack HJ. PET-CT – comments on the white paper. Eur J Nucl Med Mol Imaging 2008;35:1576. doi:10.1007/s00259-008-0844-8.

    Article  PubMed  Google Scholar 

  8. Karcher G, Als C, Goldman S, Mundler O, Sayman HB. EANM-ESR white paper on multimodality imaging. A white paper for a black project: towards the decline of nuclear medicine as an independent specialty in Europe? Eur J Nucl Med Mol Imaging 2008;35:674–6. doi:10.1007/s00259-008-0723-3.

    Article  PubMed  CAS  Google Scholar 

  9. Zlatopolskiy B, Urusova E, Morgenroth A, Schmidt F, Dinger C, Kull T, et al. 3′-(E)-(2-Iodovinyl)uridine (IVU). Synthesis and biological evaluation of the new ribonucleoside tracer. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S204.

    Google Scholar 

  10. Petrik M, Haas H, Lass-Flörl C, Helbok A, Dobrozemsky G, Virgolini I, et al. 68 Ga labelled peptide siderophores as radiopharmaceuticals for imaging pulmonary aspergillosis. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S208.

    Google Scholar 

  11. Fischer S, Deuther-Conrad W, Hiller A, Østergaard Nielsen E, Brunicardi-Timmermann D, Peters D, et al. [18F]NS10743: a potential radiotracer for imaging of alpha-7 nicotinic acetylcholine receptors (α7 nAChR). Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S172.

    Google Scholar 

  12. Sala F, Nistri A, Criado M. Nicotinic acetylcholine receptors of adrenal chromaffin cells. Acta Physiol (Oxf) 2008;192:203–12.

    CAS  Google Scholar 

  13. Barrett JA, Mairs R, Boyd M, Stubbs JB, Stabin MG, Kuehl P, et al. 131I-MIP-1145 A novel targeted radiotherapeutic for the treatment of metastatic melanoma. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S160.

    Google Scholar 

  14. Ross TL, Honer M, Mindt TL, Groehn V, Schibli R, Ametamey SM, et al. Synthesis and pharmacological evaluation of 18F-labelled folates for the PET imaging of folate receptor-positive tumours. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S152.

    Google Scholar 

  15. Finnema SJ, Donohue SR, Zoghbi SS, Brown AK, Gulyás B, Innis RB, et al. Evaluation in monkey of [11C]PipISB and [18F]PipISB as candidate radioligands for imaging brain cannabinoid type 1 (CB1) receptors in vivo. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S172.

    Google Scholar 

  16. Bekis R, Medine I, Dagdeviren K, Ertay T, Unak P. A new agent for sentinel lymph node detection. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S232.

    Google Scholar 

  17. Ishitsu T, Takahashi I, Tsuchiya K, Kawaguchi T, Yamada N, Amemiya K. Development of a small field of view gamma camera using a pixelated CdTe detector. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S146. doi:10.1007/s00259-007-0588-x.

    Google Scholar 

  18. Piscaer T, Forrer F, Weinans H, de Jong M. Highly sensitive monitoring of changes in bone metabolism as a consequence of osteoarthritis in rats using animal SPECT/CT. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S188.

    Google Scholar 

  19. Rafecas M, on behalf of the AX-PET collaboration. Development and performance of a new detector concept for high resolution PET based on wave length shifters and Geiger-mode APDs. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S166. doi:10.1007/s00259-007-0539-6.

    Google Scholar 

  20. Lecchi M, Belloli S, Bartoli A, Belcari N, Moresco RM, Simonelli P, et al. Data quantification using a YAP-based animal PET: role of energy window and calibration phantom. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S193. doi:10.1007/s00259-007-0631-y.

    Google Scholar 

  21. Bartoli A, Belcari N, Fabbri S, Panetta D, Moehrs S, Del Guerra A. Quantitative evaluation of the combined YAP-(S)PET II scanner with a high resolution small animal CT. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S194.

    Google Scholar 

  22. Varrone A, Sjoholm N, Gulyás B, Halldin C, Farde L. Point spread function reconstruction of high-resolution research tomograph – HRRT – PET-images improves in vivo neuroreceptor quantification. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S145. doi:10.1007/s00259-008-0729-x.

    Google Scholar 

  23. Conti M, Lois C, Hubner K, Long MJ, Jakoby B, Howe WC, et al. Clinical evaluation of time-of-flight imaging. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S166. doi:10.1007/s00259-007-0539-6.

    Google Scholar 

  24. Apostolova I, Wiemker R, Paulus T, Kabus S, Mishina E, Mester J, et al. Combined correction for motion blur and recovery effect in solitary pulmonary nodules detected by FDG PET/CT. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S145.

    Google Scholar 

  25. Shirmohammad M, Ay MR, Rahmim A, Sarkar S, Zaidi H. A novel energy mapping method for attenuation map generation at 511 keV in computed tomography based attenuation correction. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S146. doi:10.1007/s00259-007-0588-x.

    Google Scholar 

  26. Dimastromatteo J, Ahmadi M, Broisat A, Riou LM, Boturyn D, Dumy P, et al. In vivo molecular imaging of vascular cell adhesion molecule-1 expression in atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S131.

    Google Scholar 

  27. Morgenroth A, Schmidt FH, Deisenhofer S, Zlatopolskiy B, Glatting G, Kull T, et al. 5-I-123-Iod-4′-thio-2′-desoxyuridin (I-123-ITdU) for endo-radio-therapy (ERT) of leukaemia: preclinical studies in a HL60-xenograft mouse model. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S196.

    Google Scholar 

  28. De Jong GM, Hendriks T, Oyen WJG, Aarts F, Bleichrodt RP, Boerman OC. Radioimmunotherapy prevents anastomotic relapse of colorectal cancer in a rat model. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S148.

    Google Scholar 

  29. Melis M, Bijster-Marchand M, de Visser M, Spreeuwenberg W, de Swart J, Konijnenberg M, et al. Dose-response effect of Gelofusine on renal retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S178.

    Google Scholar 

  30. Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, et al. Intravesical α-radioimmunotherapy with Bi-213-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S179.

    Google Scholar 

  31. Malik V, Lucey JA, Duffy GJ, McNamara L, Rowley S, Wilson L. Early FDG-PET two weeks into chemoradiation did not predict histomorphological response or overall survival in patients with adenocarcinoma of the oesophagus. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S130.

    Google Scholar 

  32. Tashiro M, Duan X, Kato M, Iwata R, Itoh M, Yanai K. PET measurement of brain histamine H1 receptor occupancy of an orally-administered antihistamine, bepotastine, and its sedative property. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S130.

    Google Scholar 

  33. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–71.

    PubMed  CAS  Google Scholar 

  34. Kajander S, Joutsiniemi E, Saraste M, Pietilä M, Ukkonen H, Saraste A, et al. Hybrid PET/CT imaging allows accurate detection of coronary atherosclerosis with assessment of functionally significant stenoses. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S195.

    Google Scholar 

  35. Makowski M, Beer AJ, Alexandra K, Ebersberger U, Hoffmann E, Kasel M, et al. Molecular imaging of myocardial alpha-v-beta-3 expression in patients after myocardial infarction using [18F]galacto-RGD PET. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S131.

    Google Scholar 

  36. Ferro A, Costanzo P, Acampa W, Daniele S, Evangelista L, De Marino M, et al. The IDIS investigators: combined evaluation of myocardial perfusion and left ventricular function by gated SPECT predicts severe coronary artery disease in diabetic patients. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S168.

    Google Scholar 

  37. Strobel K, Stumpe KD, Hany TF, Soyka JD, Veit-Haibach P, Tamborrini G, et al. Comparison of 18F-fluoride PET/CT and conventional bone scintigraphy in patients with spondyloarthropathies. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S137.

    Google Scholar 

  38. Niesen A, Meister U, Boehm H, Prasad V, Baum RP. Semiquantitative evaluation of activated facet arthrosis before lumbar total disc replacement: results in 66 patients using F-18-fluoride-ion PET/CT. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S151.

    Google Scholar 

  39. Allenbach G, Pica A, Maeder P, Paschoud N, Stupp R, Bischof Delaloye A, et al. Image-based radiation therapy planning for brain tumors with F-18-fluorethyltyrosine (FET) PET and MRI: potential impact on target volume delineation. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S190.

    Google Scholar 

  40. Van der Ploeg IMC, Nieweg OE, Kroon BBR, Vogel WV, Hoefnagel CA, Valdés Olmos RA. The potential value of SPECT-CT for anatomical lymphatic mapping in patients with melanoma. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S192.

    Google Scholar 

  41. Van der Ploeg IMC, Nieweg OE, Kroon BBR, Rutgers EJT, Vogel WV, Hoefnagel CA, et al. The potential value of SPECT-CT for anatomical lymphatic mapping in patients with breast cancer. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S192.

    Google Scholar 

  42. Van Dalen JA, Hoffmann AL, Kaanders JHAM, Oyen WJG. A new concept for accurate and robust SUV determination with PET for multi-center studies and therapy response monitoring. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S189.

    Google Scholar 

  43. Schmidt M, Simon T, Hero B, Berthold F, Schicha H. Prognostic impact of I-123-mIBG scintigraphy on survival in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S144.

    Google Scholar 

  44. Wiering B, Krabbe PF, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: a randomized study. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S191.

    Google Scholar 

  45. Henriksen G, Schoultz BW, Jansen KH, Wester HJ. In-capillary chemistry for PET-tracer production. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S157. doi:10.1007/s00259-007-0705-x.

    Google Scholar 

  46. Kobe C, Dietlein M, Franklin J, Eich HT, Gossmann A, Engert A, et al. FDG-PET for assessment of residual tissue after completion of chemotherapy in Hodgkin lymphoma – report on the 2nd interim analysis of the PET investigation in the trial HD15 of the German Hodgkin Study Group (GHSG). Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S144.

    Google Scholar 

  47. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989–94. doi:10.1182/blood-2008-06-155820.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We thank Thomas Isokeit for his technical assistance.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Str. 33, 48149, Münster, Germany

    O. Schober, K. Rahbar & B. Riemann

Authors
  1. O. Schober
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Rahbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Riemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Schober.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schober, O., Rahbar, K. & Riemann, B. Multimodality molecular imaging — from target description to clinical studies. Eur J Nucl Med Mol Imaging 36, 302–314 (2009). https://doi.org/10.1007/s00259-008-1042-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-1042-4

Keywords

Search

Navigation